Evaluation of Exogenous Estrogen Use in Patients with Lobular Neoplasia and its Role in Subsequent Breast Cancer Development

Jordan Petrick; Vibhusha Kolli; Madhuchhanda Roy; Mai A. Elezaby; Meeghan A. Lautner; Laura M. Bozzuto; Ashley A. Woodfin; Heather B. Neuman; Lee G. Wilke; Anna C. Beck

doi:10.1016/j.surg.2026.110625

Back

Evaluation of Exogenous Estrogen Use in Patients with Lobular Neoplasia and its Role in Subsequent Breast Cancer Development

Journal article

Peer reviewed

Evaluation of Exogenous Estrogen Use in Patients with Lobular Neoplasia and its Role in Subsequent Breast Cancer Development

Jordan Petrick, Vibhusha Kolli, Madhuchhanda Roy, Mai A. Elezaby, Meeghan A. Lautner, Laura M. Bozzuto, Ashley A. Woodfin, Heather B. Neuman, Lee G. Wilke and Anna C. Beck

Surgery, 110625

09/03/2026

DOI: 10.1016/j.surg.2026.110625

PMCID: PMC13612942

PMID: 42786086

View Online

Abstract

There is a paucity of data around the impact of exogenous hormones on future breast cancer risk in the setting of Lobular Neoplasia (LN). We sought to determine if patients with history of exogenous hormone use who develop LN are more likely to develop a future breast cancer. Following IRB approval, a single-institution retrospective review was conducted of patients diagnosed with LCIS or ALH between 1/2009 and 12/2017. Use of exogenous hormones and future breast cancer was examined. Data were analyzed using IBM SPSS version 29.0.2.0. A total of 88 patients with LN were identified; 57 (65%) with LCIS and 31 (35%) with ALH. At time of LN diagnosis, 53 (60%) underwent surgical excision, 48 (39%) were followed in a high-risk clinic, and 13 (15%) took anti-estrogen therapy for risk reduction. 15 patients had a history of hormone therapy (HT) use prior to LN diagnosis (17%) and 3 (3%) started HT following LN diagnosis. Median overall follow-up was 9.7 years (interquartile range [IQR] 7.2-11.4). Eleven (13%) patients developed breast cancer. Comparing those who developed breast cancer vs. not, there was no difference in HT use (9% vs 21%, p=0.325), vaginal estrogen use (27% vs 9%, p=0.110), OCP use (54% vs 64%, p=0.675), or other hormone-based birth control (27% vs 14%, p=0.402). In a single-institution cohort with long-term follow up, future development of breast cancer in patients diagnosed with LN was not associated with prior use of HT, OCPs, vaginal estrogen or other hormone-based birth control use. [Display omitted]

Breast Cancer

Atypical Lobular Hyperplasia

Exogenous Hormones

Hormone Therapy

Lobular Carcinoma in Situ

Lobular Neoplasia

Details

Title: Subtitle: Evaluation of Exogenous Estrogen Use in Patients with Lobular Neoplasia and its Role in Subsequent Breast Cancer Development
Creators: Jordan Petrick - University of Wisconsin–Madison
Vibhusha Kolli - University of Wisconsin School of Medicine and Public Health
Madhuchhanda Roy - University of Wisconsin School of Medicine and Public Health
Mai A. Elezaby - University of Wisconsin School of Medicine and Public Health
Meeghan A. Lautner - University of Wisconsin–Madison
Laura M. Bozzuto - University of Colorado Anschutz
Ashley A. Woodfin - University of Wisconsin–Madison
Heather B. Neuman - University of Wisconsin–Madison
Lee G. Wilke - University of Wisconsin–Madison
Anna C. Beck - University of Wisconsin–Madison
Resource Type: Journal article
Publication Details: Surgery, 110625
DOI: 10.1016/j.surg.2026.110625
PMID: 42786086
PMCID: PMC13612942
NLM abbreviation: Surgery
ISSN: 0039-6060
Publisher: Elsevier Inc
Language: English
Electronic publication date: 09/03/2026
Academic Unit: Surgery
Record Identifier: 9985224435202771

Metrics

4 Record Views